今日药学

2020, v.30(09) 644-648

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

HER-2阳性晚期乳腺癌二线治疗新药吡咯替尼
New Second-line Drug for HER-2 Positive Advanced Breast Cancer-Pyrotinib

王彪;房文通;
WANG Biao;FANG Wentong;Department of Pharmacy,the First Affiliated Hospital of Nanjing Medical University;

摘要(Abstract):

目的为吡咯替尼的临床应用提供参考。方法以"吡咯替尼"和"pyrotinib"为关键词,组合查询2000年1月1日~2018年8月31日在中国知网、万方数据、PubMed、Web of Science等数据库中的相关文献,对吡咯替尼的基本信息、作用机制、药动学、药效学、安全性及特点进行论述。结果共检索到相关文献25篇,其中有效文献12篇。结论吡咯替尼是一种新型的小分子酪氨酸激酶抑制剂(TKI),对人表皮生长因子受体2和上皮生长因子受体均有抑制作用。吡咯替尼具有良好的药动学特点,其Ⅱ期临床研究显示了良好的疗效,故通过优先审评程序获得有条件批准上市,适应证为HER-2阳性晚期转移性乳腺癌。本文对吡咯替尼的基本信息、作用机制、药动学、药效学、安全性及特点等作一概述。
OBJECTIVE To provide the bases of clinical application of Pyrotinib.METHODS We searched literatures in the database of CNKI,Wanfang,Pubmed and Web of science by the keyword of pyrotinib from Jan 1,2000 to August 31,2018.Literatures about basic information,mechanism,pharmacokinetics,pharmacodynamics,safety and characteristics of pyrotinib were included.RESULTS25 literatures were searched,of which 12 were referenced.CONCLUSION Pyrotinib is a small molecule tyrosine kinase inhibitor that inhibits both human epidermal growth factor receptor 2(HER-2) and epidermal growth factor receptor.Pyrotinib have good pharmacokinetic characteristics and the phase Ⅱclinical trial shows significant benefit.Therefore,it can be approved to conditional listing by priority review process for the indication of HER2-positive advanced breast cancer.We make a summary about the basic information,mechanism,pharmacokinetics,pharmacodynamics,safety and characteristics of pyrotinib in this article.

关键词(KeyWords): 晚期乳腺癌;吡咯替尼;人表皮生长因子受体2;酪氨酸激酶抑制剂
advanced breast cancer;pyrotinib;human epidermal growth factor receptor 2;tyrosine kinase inhibitors

Abstract:

Keywords:

基金项目(Foundation): 常州四药医院药学科研基金(2018YX004)

作者(Author): 王彪;房文通;
WANG Biao;FANG Wentong;Department of Pharmacy,the First Affiliated Hospital of Nanjing Medical University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享